Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
SHSE:605177'
s OCF Yield % Range Over the Past 10 Years
Min: -11.27 Med: -3.49 Max: 5.42
Current: -5.9
During the past 10 years, the highest OCF Yield % of Zhejiang East-Asia Pharmaceutical Co was 5.42%. The lowest was -11.27%. And the median was -3.49%.
SHSE:605177's OCF Yield % is ranked better than 56.6% of 1410
companies
in the Biotechnology industry
Industry Median: -8.75
vs SHSE:605177: -5.90
Zhejiang East-Asia Pharmaceutical Co OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Zhejiang East-Asia Pharmaceutical Co OCF Yield % Related Terms
Zhejiang East-Asia Pharmaceutical Co OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang East-Asia Pharmaceutical Co OCF Yield % Chart
SHSE:605177 vs VRTX, REGN, RVMD: OCF Yield % Comparison
For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang East-Asia Pharmaceutical Co OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhejiang East-Asia Pharmaceutical Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Zhejiang East-Asia Pharmaceutical Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) has a OCF Yield % of -5.90 as of Jul. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. According to the industry distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #612 out of 1410 companies in the Biotechnology industry, placing it in the top 43.4%.
Is Zhejiang East-Asia Pharmaceutical Co's OCF Yield % too high?
Zhejiang East-Asia Pharmaceutical Co's current OCF Yield % is -5.90. Based on the distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #612 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhejiang East-Asia Pharmaceutical Co has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang East-Asia Pharmaceutical Co's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #612 out of 1410 companies for OCF Yield %. This puts Zhejiang East-Asia Pharmaceutical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. Zhejiang East-Asia Pharmaceutical Co's current OCF Yield % is -5.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang East-Asia Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥12.42, compared to a current price of ¥15.10 — trading 21.6% above its estimated fair value. The current OCF Yield % is -5.90. Zhejiang East-Asia Pharmaceutical Co's overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Zhejiang East-Asia Pharmaceutical Co (SHSE:605177), the current OCF Yield % is -5.90 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥15.10 is trading 21.6% above its estimated GF Value™ of ¥12.42.
GuruFocus considers Zhejiang East-Asia Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:605177:
OCF Yield %: -5.90
GF Value™: ¥12.42 vs. price of ¥15.10 (21.6% above fair value)
No single metric tells the full story. See the SHSE:605177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang East-Asia Pharmaceutical Co Business Description
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
62GF Score
Get the complete analysis for SHSE:605177
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605177 has been successfully added to your 
